9,605 Shares in Axsome Therapeutics, Inc. $AXSM Bought by Integrity Alliance LLC.

Posted by Geri Gentry on May 28th, 2026

Integrity Alliance LLC. bought a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 9,605 shares of the company’s stock, valued at approximately $1,754,000.

A number of other hedge funds have also modified their holdings of the stock. Vanguard Group Inc. grew its holdings in shares of Axsome Therapeutics by 6.0% in the 3rd quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company’s stock worth $507,739,000 after acquiring an additional 235,626 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Axsome Therapeutics by 84.1% in the 3rd quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock worth $162,082,000 after acquiring an additional 609,516 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Axsome Therapeutics by 73.3% in the 3rd quarter. Invesco Ltd. now owns 990,557 shares of the company’s stock worth $120,303,000 after acquiring an additional 419,008 shares during the last quarter. State Street Corp grew its holdings in shares of Axsome Therapeutics by 5.8% in the 2nd quarter. State Street Corp now owns 958,503 shares of the company’s stock worth $100,058,000 after acquiring an additional 52,483 shares during the last quarter. Finally, Deep Track Capital LP grew its holdings in shares of Axsome Therapeutics by 12.3% in the 3rd quarter. Deep Track Capital LP now owns 900,000 shares of the company’s stock worth $109,305,000 after acquiring an additional 98,629 shares during the last quarter. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Axsome Therapeutics Stock Performance

Shares of AXSM stock opened at $234.52 on Thursday. Axsome Therapeutics, Inc. has a 1-year low of $96.09 and a 1-year high of $238.56. The company has a current ratio of 1.39, a quick ratio of 1.32 and a debt-to-equity ratio of 2.27. The company has a market capitalization of $12.07 billion, a price-to-earnings ratio of -62.87 and a beta of 0.59. The stock’s fifty day simple moving average is $192.56 and its 200-day simple moving average is $174.16.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last issued its quarterly earnings results on Monday, May 4th. The company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 267.16%. The business had revenue of $191.20 million for the quarter, compared to analysts’ expectations of $191.10 million. The company’s revenue for the quarter was up 57.4% compared to the same quarter last year. On average, sell-side analysts predict that Axsome Therapeutics, Inc. will post -2.14 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Axsome Therapeutics news, insider Ari Maizel sold 7,500 shares of the business’s stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $182.42, for a total value of $1,368,150.00. Following the transaction, the insider owned 7,500 shares in the company, valued at $1,368,150. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Mark L. Jacobson sold 4,517 shares of the business’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $227.94, for a total value of $1,029,604.98. Following the completion of the transaction, the chief operating officer owned 4,517 shares in the company, valued at $1,029,604.98. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 12,250 shares of company stock worth $2,450,921 in the last quarter. 20.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on AXSM shares. Cantor Fitzgerald restated an “overweight” rating and issued a $272.00 target price on shares of Axsome Therapeutics in a report on Monday, May 4th. Wells Fargo & Company lifted their target price on Axsome Therapeutics from $225.00 to $255.00 and gave the stock an “overweight” rating in a report on Tuesday, May 5th. Wolfe Research assumed coverage on Axsome Therapeutics in a report on Monday, February 23rd. They issued an “outperform” rating and a $230.00 target price on the stock. Morgan Stanley lifted their price target on Axsome Therapeutics from $217.00 to $242.00 and gave the company an “equal weight” rating in a report on Tuesday, May 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Axsome Therapeutics in a report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Axsome Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $251.26.

Get Our Latest Report on AXSM

Axsome Therapeutics Profile

(Free Report)

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.